Aspergillus GM Lateral Flow Assay



REF: AF2003 **C€**: Serum, BAL

It's About Time



Test Features

- Results in Less than an Hour
- Reduces Time to Proper Patient Care



The LFA could aid in quick clinical decisions in ICU patients, which could lead to increased survival of patients with true IPA.⁵


The IMMY sōna Aspergillus galactomannan LFA has been suggested as a diagnostic tool in the 2020 ECMM CAPA-IAA-ICU management algorithm guidelines.¹

Good agreement to existing product, better agreement to EORTC (true disease status):

Performance of IMMY ASP LFA	Specimen	Sensitivity	Specificity	NPV
vs. Proven IA²	Serum & BAL	100%	95.5%	
vs. Probable IA ²	Serum & BAL	87.5%	96.2%	
vs. Proven IPA³	BAL	91%	92%	99%
vs. EORTC/MSG⁴	Serum	91%	91%	
vs. 2008 EORTC/MSG⁵	BAL	88%	81%	94%
vs. EORTC excluding GM⁵	BAL	100%	81%	96%
vs. AspICU⁵	BAL	94%	81%	97%
vs. modified AsplCU⁵	BAL	87%	81%	94%
vs. modified AspICU excluding GM ⁵	BAL	97%	81%	98%

^{1.} ECMM. COVID-19/Influenza-Associated Pulmonary Aspergillosis – Management. 2020

^{5.} Mercier T, et al. Point of care aspergillus testing in intensive care patients. Crit Care. 2020.



LFA Cube Reader provides objective numeric value and allows for easy batch testing.

CONTACT US

Ready to evaluate today?

Contact us for a validation kit now.



^{2.} Jani K, McMillen T, Morjaria S, Babady NE. Performance of the sona Aspergillus Galactomannan Lateral Flow Assay in a Cancer Patient Population. J Clin Microbiol. 2021; JCM0059821.

^{3.} Mercier T, et al. Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. Med Mycol. 2019.

^{4.} Serin I, Dogu MH. Serum Aspergillus galactomannan lateral flow assay for the diagnosis of invasive aspergillosis: A single-centre study. Mycoses. 2021;64(6):678-683.